
Source MS Trust: The MS Trust is delighted that Ocrevus (ocrelizumab) has been approved by NICE for NHS treatment of early, inflammatory primary progressive MS. NICE has approved Ocrevus for people with primary progressive MS if they: have had symptoms of primary progressive MS for 15 years or less and are able to walk 20 metres or more, with or without walking aids (up… Read more »